Last Updated: 01/01/2025
Phase 1/2a controlled human malaria infection (CHMI) clinical trial – RTS,S-AS01/ChAd63-TRAP/MVA-TRAP
Objectives
RTS,S/AS01, which induces immune responses to the pre-erythrocytic circumsporozoite protein (CSP), is the most clinically advanced malaria vaccine candidate in development and has shown moderate efficacy in a Phase 3 trial in Africa. However, higher levels of efficacy would be desirable.
One potential means of achieving this would be to combine the RTS,S/AS01 vaccine candidate with another vaccine candidate that showed repeatable efficacy in previous human trials.
This project combines GSK’s RTS,S/AS01 vaccine candidate with Oxford University’s ChAd63 and MVA viral vector vaccine candidates expressing ME-TRAP (multiple malaria epitopes fused to thrombospondin related adhesion protein), to determine if significant improvement in protective efficacy over RTS,S/AS01 alone can be achieved.
It is hypothesized that the combined approach will induce both antibody and cell-mediated immunity to the two antigens, CSP and ME-TRAP, which might lead to enhanced efficacy.
Related Resources
